Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Therapeutic Antibody Development Platforms

Therapeutic antibodies can bind to specific proteins on the cell surface, and more and more therapeutic antibodies are being used in biopharmaceutical research. With a professional technical team and advanced antibody development platform, our company has the capabilities and resources to provide one-stop therapeutic antibody development solutions. Our experts provide you with project support and communication throughout the process to ensure that we can respond quickly to the changing needs of your rare disease therapy research project.

Therapeutic Antibody for Rare Diseases

In 1986, the first therapeutic monoclonal antibody (mAb) was approved. During this period, therapeutic antibody drugs have been rapidly developed. Due to their high specificity and few adverse reactions, antibody drugs are widely used in research in the fields of cancer, autoimmunity, inflammation, and infectious diseases. There are already some cases of therapeutic antibodies being used to treat rare diseases, such as Rituxan is used to treat non-hodgkins lymphoma and Remicade is used to treat Crohn's disease.

2-1-3 Therapeutic Antibody Development Platforms-1Fig.1 Targets for antibody therapeutics approved or in regulatory review globally for diseases. (Wang, Z., et al., 2022)

Technologies for Therapeutic Antibody Development

  • Traditional Animal Immunization Technology
    The antigen is injected into the animal to stimulate B cell differentiation and maturation. The animal serum is collected to isolate and purify the antibody.
  • Hybridoma Technology
    Animals are immunized with antigens, and the collected splenocytes are fused with myeloma cells to produce hybridoma cells that continue to secrete antibodies.
  • Single B Cell Technology
    Single B cell technology utilizes the characteristic that each B cell only produces one specific antibody, amplifying the antibody gene directly from a single B cell to obtain antigen-specific antibodies.
  • Antibody Library Screening Technology
    Phage display technology can clone a large number of antibody gene libraries and select and combine with desired targets. In addition, there are in vitro display technologies represented by ribosome display and mRNA display, and cell surface display technologies represented by yeast display.

Our Services

With a comprehensive array of antibody discovery technologies, such as hybridoma technology, phage display technology, and single B cell antibody screening technology, as well as antibody optimization and characterization platforms such as antibody humanization, antibody affinity maturation, KD measurement and epitope mapping, our company provides comprehensive, high-quality, and customizable therapeutic antibody development services.

Polyclonal Antibody Development Platform Monoclonal Antibody Development Platform
Polyclonal antibodies are a heterogeneous mix of antibodies formed by a variety of B cells in the body. Our company is confident to provide customers with polyclonal antibody development services for rare diseases. Monoclonal antibodies (mAb) are highly uniform antibodies produced by a single B cell clone and only target a specific antigenic epitope. Over the years, our company has been committed to the construction and improvement of antibody development platforms.
Bispecific Antibody (BsAb) Development Platform Antibody-drug Conjugates Development Platform
Bispecific antibodies are artificial antibodies containing two specific antigen-binding sites. With extensive experience and expertise in cell fusion or recombinant DNA technology, our company provides the production and expression of bispecific antibodies. Antibody-drug conjugate (ADC) consists of monoclonal antibodies, cytotoxic payloads, and molecular linkers. From ADC preparation to bioanalysis, our company provides end-to-end ADC development services. Our advanced platform can meet any of your needs.
Single Domain Antibody Development Platform
Single domain antibodies (sdAb) can selectively bind to specific antigens and are widely used in the development of new drugs and the diagnosis of diseases. With the world's leading technology, our company can immunize various animals such as camels to support the development of sdAb.

Why Choose Us?

  • Ability to customize products and services
  • Providing standardized upstream platform solutions
  • Expertise and experience in the industry
  • High data quality and reliable analysis
  • Economical pricing and fast turnaround time
  • Ph.D.-level scientists and skilled technicians

Antibody Therapy Development Workflow

With many years of experience and a proven track record of quality, innovation, and customer support, our company provides comprehensive services for leading and emerging biopharmaceutical companies and scientific research institutions to develop therapeutic antibodies for rare diseases. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Wang, Z., et al. "Development of therapeutic antibodies for the treatment of diseases." Molecular Biomedicine 3.1 (2022): 35.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.